Drug Profile
Influenza virus vaccine live intranasal (trivalent) - AstraZeneca
Alternative Names: CAIV-T; Fluenz; FluMist; Influenza vaccine live intranasal; Trivalent live attenuated seasonal influenza vaccine - AstraZenecaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer AstraZeneca
- Class Influenza virus vaccines live; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 02 Jul 2019 Influenza virus vaccine live intranasal is not yet available for Influenza virus infections (Prevention) in Liechtenstein, Iceland (Intranasal)
- 30 Jun 2016 Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends against the use of FluMist®
- 01 Feb 2012 Launched for Influenza virus infections in United Kingdom (Intranasal)